Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343572 · ClinicalTrials.gov registry record · Early Phase 1
Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium
A Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium, sponsored by Hugh Taylor.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05343572 is a Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium that is actively recruiting participants, run by Hugh Taylor. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05343572, a Early Phase 1 study of Asherman Syndrome and Atrophic Endometrium, is actively recruiting participants, sponsored by Hugh Taylor.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).
Conditions Studied
Interventions
- DRUG Plerixafor
Study Locations (1)
Connecticut
- Yale Fertility Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05343572
The ClinicalTrials.gov registry entry for NCT05343572 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hugh Taylor, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Asherman Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Plerixafor is the first listed.
NCT05343572 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05343572 about?
NCT05343572 is a clinical study titled "Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium". This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Impla...
What is the current status of trial NCT05343572?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2023-11-01. Estimated completion is 2027-12.
What conditions does trial NCT05343572 study?
This clinical trial studies the following conditions: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure.
What interventions are being tested in trial NCT05343572?
The interventions under investigation include: Plerixafor (DRUG).
Who is sponsoring clinical trial NCT05343572?
This trial is sponsored by Hugh Taylor, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05343572 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.